18:10 , Apr 23, 2019 |  BioCentury  |  Finance

Accelerating innovations in Cambridge

As the Cambridge, U.K., life sciences start-up environment continues to flourish, Cambridge Innovation Capital’s Michael Anstey believes the city lacked a crucial element to foster start-ups’ growth: a “true U.S.-style accelerator” to provide capital, mentorship...
17:57 , Sep 7, 2018 |  BC Week In Review  |  Financial News

Winter, Jackson, Ramakishnan, Balasubramaniam among co-founders of new U.K. fund Ahren

Ahren Innovation Capital LLP (Cambridge, U.K.) announced the first close of its Ahren LP fund with over $100 million from Aviva, Wittington Investments and undisclosed U.S. family offices. The fund declined to disclose the exact...
23:29 , Sep 4, 2018 |  BC Extra  |  Financial News

Winter, Jackson, Ramakishnan, Balasubramaniam among co-founders of new U.K. fund Ahren

Ahren Innovation Capital LLP (Cambridge, U.K.) announced the first close of its Ahren LP fund with over $100 million from Aviva, Wittington Investments and undisclosed U.S. family offices. The fund declined to disclose the exact...
00:47 , Jul 27, 2018 |  BC Innovations  |  Product R&D

Syncona’s sister act

With the final pieces of its gene therapy portfolio in place, Syncona Investment Management Ltd. thinks its five “sister companies” are poised to capitalize on recent regulatory and technological advances in gene therapy, and push...
22:53 , Nov 3, 2017 |  BC Extra  |  Company News

Management tracks: Tissue Regenix, Therapix

Regenerative medical device company Tissue Regenix Group plc (LSE:TRX) named Steve Couldwell CEO. A Tissue Regenix director since 2013, Couldwell was COO of global biosurgery at Sanofi (Euronext:SAN; NYSE:SNY). Cannabinoid company Therapix Biosciences Ltd. (Tel...
00:55 , Nov 8, 2016 |  BC Extra  |  Financial News

Syncona pooling resources with U.K. cancer investors

The Syncona investment arm of the Wellcome Trust and cancer-focused investment firm BACIT Ltd. (LSE:BACT) proposed a deal in which they would combine to form a publicly traded life sciences investment company with about L1...
07:00 , Mar 21, 2016 |  BC Week In Review  |  Financial News

Cambridge Epigenetix completes venture financing

Cambridge Epigenetix Ltd. , Babraham, U.K.   Business: Genomics, Supply/Service   Date completed: 2016-03-14   Type: Venture financing   Raised: $21 million   Investors: GV; Sequoia Capital; New Science Ventures; Syncona Partners LLP; Cambridge University...
01:06 , Mar 15, 2016 |  BC Extra  |  Financial News

Cambridge Epigenetix raises $21M in series B round

Cambridge Epigenetix Ltd. (Babraham, U.K.) raised $21 million in a series B round led by new investor GV. New investor Sequoia Capital also participated, as did existing investors New Science Ventures, Syncona Partners and Cambridge...
08:00 , Feb 26, 2015 |  BC Innovations  |  Finance

Europe waking to the American dream

While Europe didn't see the spike in seed and series A financing that the U.S. biotech sector enjoyed in 2014, there are signs the region is beginning to capitalize on the strength of its academic...
08:00 , Nov 3, 2014 |  BC Week In Review  |  Financial News

Cambridge Epigenetix completes venture financing

Cambridge Epigenetix Ltd. , Babraham, U.K.   Business: Genomics, Supply/Service   Date completed: 2014-10-29   Type: Venture financing   Raised: $5.5 million   Investors: New Science Ventures; Syncona Partners LLP; Cambridge Enterprise  ...